Varda’s orbit-made drugs plan now faces the hardest test: repetition

According to the source material, varda Space Industries has secured its first major commercial partner for in-orbit drug manufacturing. The startup, founded in 2021 by Delian Asparouhov and Will Bruey, announced a deal with United Therapeutics to produce pharmaceuticals in microgravity—a move that could redefine drug development. Unlike past experiments confined to the International Space Station, Varda’s approach relies on frequent SpaceX launches to send small satellites equipped with experimental capsules into orbit.

These capsules, roughly the size of a moving truck, are designed to process drugs in space before returning to Earth at speeds of Mach 25.

The collaboration marks a shift from government-led research to private-sector innovation in space-based manufacturing. United Therapeutics, led by CEO Martine Rothblatt—a former satellite telecommunications entrepreneur—sees potential in microgravity’s unique conditions to create "even more amazing" versions of its drugs, as Rothblatt described. Varda’s chief strategy officer, Michael Reilly, framed the deal as "the first commercial path to products made in space," signaling a broader ambition to turn orbital labs into profit-driven factories.

The source material also shows that historically, space manufacturing has been limited to small-scale experiments, often constrained by the high costs and logistical challenges of the ISS. Varda’s model aims to overcome these barriers by leveraging SpaceX’s launch cadence—currently averaging a mission every two to three days—to make orbital production more accessible.

The startup’s first satellite launches in 2023 demonstrated the feasibility of its approach, though the scale and timeline of commercial drug production remain unproven.

The scientific rationale for microgravity drug manufacturing lies in its potential to alter molecular structures in ways impossible on Earth. Without gravity’s interference, proteins and crystals can form more uniformly, potentially leading to drugs with improved stability, solubility, or therapeutic effects. For pharmaceutical companies, this could mean extended patent lifecycles or entirely new treatments. However, the industry will be watching closely to see whether the benefits outweigh the costs—and whether regulators are prepared to approve drugs manufactured beyond Earth’s atmosphere.

Varda’s upcoming missions will serve as a critical test of this model. If successful, the startup could position itself as a pioneer in a nascent but high-stakes market, where the line between science fiction and industrial reality grows increasingly thin. The real question is no longer if space-based manufacturing is possible, but how soon it becomes a routine part of the pharmaceutical supply chain.